Quick answer
What does high purity mean for CJC-1295 (No DAC)? The listed sequence has four substitutions versus native GHRH(1-29): D-Ala2, Gln8, Ala15 and norleucine27, giving C152H252N44O42 and an average mass of about 3,367.95 g/mol. High purity needs an HPLC percentage plus a measured mass matching that value, since the L-Ala2 epimer and build-error sequences are not distinguished by a percentage alone.
When researchers search for a high-purity CJC-1295 source, they are looking for assurance that the vial contains what the label says. Assurance comes from checks, and the checks depend on the molecule. This article derives them from the sequence listed on the product page. For laboratory research use only; not for human consumption.
What the product page tells you to check
The CJC-1295 (No DAC) product page describes a modified GRF (1-29) GHRH analog without the Drug Affinity Complex, supplied as a lyophilized powder in 5 mg and 10 mg sizes, with purity stated as ≥98% by HPLC and storage at 2–8 °C (−20 °C for the long term) protected from heat, moisture and light. Unlike many listings, it also gives a molecular formula, C152H252N44O42, and a full sequence with two non-standard residues: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg. Those two entries are what make an identity check possible, and they are the basis of this article.
Searches for "sourcing high purity CJC-1295" are really asking what "high purity" has to mean for this peptide before a lab relies on it. The answer is more specific than a percentage. A 29-residue peptide with four substitutions relative to the native sequence has a defined set of look-alike impurities, and most of them are invisible to an HPLC percentage alone. The library already covers the compound overview and purity testing; this article works from the sequence outward and gives a verification worksheet.
The four substitutions and the formula arithmetic
The listed sequence differs from the native human GHRH(1-29) sequence (the sermorelin sequence, Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg) at four positions. The native sequence is the one isolated from tumor and hypothalamic tissue in the early 1980s [1][2]; in plasma the native hormone is inactivated by N-terminal cleavage that removes the first two residues, the site where the analog carries D-Ala [3].
| Position | Native residue | Analog residue | Chemical logic | Formula change |
|---|---|---|---|---|
| 2 | L-Ala | D-Ala | D-amino acid at the peptidase cleavage site; same formula, different stereochemistry | None (stereoisomer) |
| 8 | Asn | Gln | Removes the deamidation-prone Asn-Ser pair [4] | +CH2 |
| 15 | Gly | Ala | Side-chain methyl added | +CH2 |
| 27 | Met | Nle (norleucine) | Isosteric replacement lacking the oxidizable thioether [5] | −S, +CH2 |
Starting from the sermorelin formula on its product page (C149H246N44O42S) and adding three CH2 units while removing one sulfur gives C152H252N44O42, exactly the formula on the CJC-1295 (No DAC) page. That agreement is a useful internal consistency check on the listing, and it also shows that the page is describing the amidated peptide. From the formula, the average mass is about 3,367.95 g/mol and the monoisotopic mass about 3,365.89 Da, calculated with standard atomic masses. The difference from sermorelin is about +10 Da average (3,367.95 versus 3,357.9). Two molecules that differ by 10 Da are easily separated by a mass spectrometer, which is why a mass measurement distinguishes this analog from the native peptide even though the sequences are 86% identical.
Impurities specific to this sequence
Synthetic peptides carry process-related impurities: deletion sequences, truncations, incompletely deprotected chains and diastereomers. The solid-phase method used to build them is described in the foundational literature [6][7]. For this peptide the substitutions create four impurity classes that a general purity percentage does not separate by name.
| Impurity class | How it arises | Mass shift vs the target | Detected by |
|---|---|---|---|
| L-Ala2 epimer (diastereomer) | Racemization of D-Ala during coupling, or L-Ala used in error | 0 Da | Chiral or high-resolution RP-HPLC; mass alone cannot see it |
| Met27 instead of Nle27 | Wrong building block | +17.96 Da (S replaces CH2) | LC-MS |
| Asn8 instead of Gln8 | Wrong building block | −14.02 Da | LC-MS |
| Gly15 instead of Ala15 | Wrong building block | −14.02 Da | LC-MS |
| Deletion at a single position | Incomplete coupling | Minus one residue mass (57–186 Da) | LC-MS; RP-HPLC peak shoulder |
| Gln8 deamidation product | Side-chain hydrolysis of Gln | +0.984 Da | High-resolution LC-MS [4] |
| Oxidized Met27, if Met was wrongly incorporated | Oxidation of the thioether | +15.995 Da | LC-MS [5] |
The table has two practical consequences. The L-Ala2 epimer has the identical mass and is the hardest to detect, which matters because the D-Ala at position 2 is the structural feature that gives the analog its resistance to the N-terminal peptidase that cleaves the native peptide [3]. And the −14.02 Da species from Asn8 or Gly15 build-errors are within the isotope envelope width of a low-resolution instrument, so mass accuracy matters. A certificate that lists a measured mass should be read against the calculated 3,367.95 average or 3,365.89 monoisotopic value to within the instrument's stated accuracy.
What "high purity" has to cover
HPLC purity of ≥98% is a statement about the main peak's share of the integrated chromatogram at one wavelength and one gradient. It does not state net peptide content, the counterion, the residual water, or the presence of co-eluting species. Quality specifications for peptide drug substances, reviewed by Vergote and colleagues, set out identity, related substances and content as separate attributes with compendial limits that differ between pharmacopoeias [8], and a research-grade certificate does not claim to meet them. The library article on what an HPLC percentage cannot tell you develops the point further.
The counterion deserves its own line. Trifluoroacetate is the usual counterion after reverse-phase purification, and exchange to another salt can be partial; a comparison of methods found that HPLC and resin routes gave partial to almost complete exchange [9]. In fetal rat osteoblast cultures, trifluoroacetate at 10-8 to 10-7 M reduced cell numbers and thymidine incorporation, and the authors advised converting peptides to a hydrochloride or equivalent salt before testing biological effects [10]. The product page does not list a counterion, so it is a question for the certificate or the supplier.
A verification worksheet
The worksheet below can be completed from the product page and a certificate of analysis, and it ends with a decision for the lab: use, hold or query.
| Item | Expected for this listing | Source of expected value | Result |
|---|---|---|---|
| Sequence includes D-Ala2, Gln8, Ala15, Nle27 | Yes | Product page | Compare with certificate |
| Formula | C152H252N44O42 | Product page | Compare |
| Average mass | ≈3,367.95 g/mol | Calculated from formula | Within instrument accuracy |
| Monoisotopic mass | ≈3,365.89 Da | Calculated from formula | Within instrument accuracy |
| Observed mass reported | Present, with method | Certificate | Present or absent |
| HPLC purity | ≥98%, method and wavelength given | Product page, certificate | Method described or not |
| Lot number matches vial | Yes | Certificate, vial label | Match or not |
| Test date | Recent relative to receipt | Certificate | Date |
| Counterion and net peptide content | Stated | Certificate | Stated or absent |
| Appearance | White to off-white lyophilized cake | Receiving record | Observed |
Where an item cannot be completed, record the gap before the first experiment; a missing field is a finding. How to read a COA, HPLC versus mass spectrometry and understanding HPLC purity explain each field, and the COA library lists published certificates. At the time of writing the product page showed the certificate as in progress, so the worksheet starts with the page values and a certificate must be requested or awaited before the remaining rows can be completed.
After receipt: handling that protects the identity you verified
Verification is wasted if the material degrades before use. The stability literature identifies the main risks for peptides: oxidation, deamidation, aggregation, adsorption to surfaces and freeze-thaw stress [5][11][12]. The analog removes two of them by design (Met replaced by Nle, Asn replaced by Gln), which lowers but does not remove the others. Keep the vial sealed and cold as the product page states, avoid repeated freeze-thaw of reconstituted solution, use low-binding labware for dilute working solutions [13], and record the date of reconstitution. The bench steps are covered in the CJC-1295 No DAC reconstitution workflow; the calculator handles the division from label mass and diluent volume, with the molar mass above as the formula input.
To place this analog among its relatives, CJC-1295 with and without DAC explains the form that adds albumin binding, and CJC-1295 versus sermorelin compares it with the native fragment; the shop lists the catalog.
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.
Frequently asked questions
What does "high purity" mean for CJC-1295 (No DAC)?
At minimum, a stated HPLC purity with its method, an observed mass matching the calculated value for C152H252N44O42, and documented lot and test date. Counterion and net content should also be reported.
What is the formula of CJC-1295 (No DAC) on the product page?
C152H252N44O42, which is the sermorelin formula plus three CH2 units minus sulfur, with an average mass of about 3,367.95 g/mol.
What are the four substitutions relative to native GHRH(1-29)?
D-Ala at position 2, Gln at 8, Ala at 15 and norleucine at 27.
Why is the L-Ala2 epimer hard to detect?
It has exactly the same mass as the target, so mass spectrometry alone cannot see it; it needs a high-resolution or chiral chromatographic method.
Why is norleucine used instead of methionine?
Norleucine is isosteric with methionine but lacks the oxidizable thioether, so one oxidation route is removed.
Does a ≥98% HPLC figure tell me the net peptide content?
No. It is the main peak's share of the chromatogram, not the peptide fraction of the powder, which also contains counterions and water.
Does the product page state the counterion?
No. Check the certificate or ask the supplier.
Which mass should I compare an LC-MS result with?
About 3,365.89 Da for the monoisotopic mass or 3,367.95 for the average mass, both calculated from the formula; the certificate's own measured value should be within the instrument accuracy.
What should I do if a certificate field is missing?
Record the gap before the first experiment and ask the supplier; do not infer the value.
Related reading: CJC-1295 No DAC Storage and Stability Explained.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-7. doi:10.1126/science.6812220
- Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982;21(24):6037-40. doi:10.1021/bi00267a002
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-794. PMID: 3805008
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb00939.x
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
- Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-9. doi:10.1002/psc.951
- Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-83. doi:10.1152/ajpendo.1999.277.5.E779
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
